Lisata Therapeutics Inc. (LSTA)
| Bid | 2.36 |
| Market Cap | 22.06M |
| Revenue (ttm) | 1.07M |
| Net Income (ttm) | -18.92M |
| EPS (ttm) | -2.23 |
| PE Ratio (ttm) | -1.13 |
| Forward PE | -2.37 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 2.65 |
| Volume | 38,799 |
| Avg. Volume (20D) | 33,298 |
| Open | 2.38 |
| Previous Close | 2.43 |
| Day's Range | 2.38 - 2.61 |
| 52-Week Range | 1.87 - 4.20 |
| Beta | 1.04 |
| Ex-Dividend Date | n/a |
About LSTA
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for LSTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
5 days ago · proactiveinvestors.com
Lisata Therapeutics is pioneering new treatments for solid tumorsDeep Dive - Lisata Therapeutics Inc
1 week ago · proactiveinvestors.com
Lisata Therapeutics inks global product license deal with CatalentLisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a global product license agreement with Catalent Inc, which would allow Catalent to incorporate Lisata's certepetide into antib...
2 weeks ago · proactiveinvestors.com
Lisata Therapeutics reveals 'encouraging' preliminary data from pancreatic cancer treatment trialLisata Therapeutics Inc (NASDAQ:LSTA) announced what it called “encouraging” preliminary data from the pancreatic ductal adenocarcinoma (PDAC) cohort of the Phase 1/2a CENDIFOX trial. The clinical-st...
2 months ago · seekingalpha.com
Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call TranscriptLisata Therapeutics, Inc. (NASDAQ:LSTA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David J. Mazzo - President, CEO & Director James Nisco - Senior VP of Finance, ...
2 months ago · proactiveinvestors.com
Lisata Therapeutics advances lead cancer drug, expects key trial results by year-endLisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it is making steady progress in advancing its pipeline of oncology drug candidates, with several key clinical trial readouts anticipated through ...
3 months ago · proactiveinvestors.com
Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary resultsLisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is evaluating Lisata's therapy candidate certepetide in combinat...